Pharmascience Inc.

Pharmascience Inc. is a privately held pharmaceutical company headquartered in Montreal, Quebec, Canada. Established in 1983 by pharmacists Morris Goodman and Ted Wise, the company has grown to become the largest Canadian-owned pharmaceutical manufacturer and the largest pharmaceutical employer in Quebec, employing over 1,600 individuals. Pharmascience specializes in the development, manufacturing, and distribution of generic, branded, and over-the-counter pharmaceuticals, serving both the Canadian and international markets. With a portfolio of over 1,300 stock-keeping units (SKUs) across 300 molecules, the company distributes its products to more than 50 countries worldwide.

In 2024, Pharmascience was recognized by Great Place to Work as one of the Top 50 Best Workplaces in Canada, reflecting its commitment to employee satisfaction and organizational excellence. The company's mission is to make essential treatments affordable, ensuring the well-being of the communities it serves.

Pharmascience operates a robust distribution network to support its global operations. The company's primary manufacturing and distribution facilities are located in Montreal and Candiac, Quebec. These state-of-the-art facilities enable Pharmascience to produce and distribute a wide range of pharmaceutical products efficiently. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Pharmascience's extensive distribution network ensures that its products are available in over 50 countries, meeting the needs of both domestic and international markets.

Pharmascience Inc. plays a pivotal role in Canada's pharmaceutical supply chain as a leading manufacturer and distributor of generic and branded medications. The company serves as a primary wholesaler, supplying pharmaceutical products to hospitals, pharmacies, and other healthcare providers across Canada. Its extensive product portfolio and manufacturing capabilities position Pharmascience as a key player in ensuring the availability of affordable and high-quality medicines within the Canadian healthcare system.

Pharmascience's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, CIPLA LIMITED. The company's total import value from India stands at $4.3 million USD, with 97 shipments comprising 21 unique formulations. CIPLA LIMITED accounts for $836,000 USD of this total, representing 31 shipments and 100% of the Indian suppliers.

This sourcing concentration indicates a strategic partnership between Pharmascience and CIPLA LIMITED, potentially leading to favorable terms and streamlined supply chain operations. However, such dependency also introduces risks related to supply chain disruptions, regulatory changes, or geopolitical factors affecting the supplier's operations. The stability of this relationship is crucial for Pharmascience's ability to maintain a consistent supply of pharmaceutical products.

Pharmascience's supply chain resilience is closely tied to its reliance on CIPLA LIMITED as the primary supplier for its pharmaceutical imports from India. The company's import data reveals a high degree of concentration, with CIPLA LIMITED accounting for 100% of the Indian suppliers.

This single-source dependency may pose challenges in terms of supply chain flexibility and responsiveness to market changes. The absence of backup suppliers for Indian imports suggests a need for strategic diversification to mitigate potential risks. Additionally, the limited diversity in imported formulations, with only 21 unique formulations, may impact Pharmascience's ability to adapt to evolving market demands.

Pharmascience's sourcing pattern, characterized by a high degree of concentration with CIPLA LIMITED, has significant strategic implications. For Pharmascience, this focused sourcing approach may lead to cost efficiencies and stronger supplier relationships. However, the lack of diversification introduces risks related to supply chain disruptions, regulatory changes, or geopolitical factors affecting the supplier's operations.

For Indian exporters, Pharmascience's sourcing strategy presents both opportunities and challenges. While the existing partnership with CIPLA LIMITED may limit immediate opportunities, Pharmascience's emphasis on affordability and quality suggests potential interest in exploring alternative suppliers that can meet these criteria. Indian exporters seeking to become alternative suppliers should focus on demonstrating compliance with international quality standards, competitive pricing, and the ability to meet Pharmascience's specific product requirements.

In Canada, the regulation of pharmaceutical imports is overseen by Health Canada, the federal department responsible for national public health. The importation and exportation of health products, including pharmaceuticals, are governed by the Food and Drugs Act and its associated Regulations. (canada.ca)

Health Canada's regulatory framework ensures that all imported pharmaceutical products meet stringent safety, efficacy, and quality standards before they are authorized for sale in Canada. This includes a comprehensive evaluation process for new drug submissions, as well as ongoing monitoring and compliance activities to maintain the integrity of the Canadian pharmaceutical market.

Import licensing requirements for pharmaceutical products in Canada are stringent, with all imported drugs required to be authorized by Health Canada before they can be sold or distributed. This process involves a thorough review of the product's safety, efficacy, and quality data. (canada.ca)

Good Manufacturing Practice (GMP) certification is a critical component of the import authorization process. Health Canada recognizes GMP certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Pharmaceutical manufacturers seeking to export to Canada must ensure that their facilities comply with these recognized GMP standards to facilitate the importation process.

Imported pharmaceutical products must undergo batch testing to verify their quality, safety, and efficacy. Health Canada requires that all drug products meet the specifications outlined in their approved drug submissions. (canada.ca)

Stability requirements are also enforced to ensure that pharmaceutical products maintain their quality throughout their shelf life. Labeling must be in both English and French, as per Canada's official language requirements. Additionally, serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market.

Between 2024 and 2026, Health Canada has implemented several policy changes affecting pharmaceutical imports. These include updates to the Food and Drugs Act and its associated Regulations, aimed at enhancing the safety and efficacy of imported health products. Specific details of these changes are outlined on Health Canada's official website. (canada.ca)

Pharmascience's product strategy focuses on therapeutic areas such as cardiovascular, advanced diabetes medications, and analgesics & antipyretics. The company's import data indicates that these categories constitute a significant portion of its pharmaceutical imports from India.

The emphasis on these therapeutic areas aligns with the growing demand for treatments addressing chronic conditions prevalent in Canada. By focusing on these segments, Pharmascience aims to provide essential medications that improve patient outcomes and quality of life.

Pharmascience's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, with a notable concentration on products from CIPLA LIMITED. This approach allows Pharmascience to leverage India's manufacturing capabilities and cost advantages while ensuring product quality.

The company's preference for finished formulations over raw active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market products, streamlining the supply chain and reducing time to market. India's established pharmaceutical industry, with its adherence to international quality standards, makes it a strategic partner for Pharmascience's procurement needs.

Pharmascience's product mix positions the company to serve various segments of the Canadian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's extensive portfolio of generic and branded medications enables it to meet the diverse needs of healthcare providers and patients across the country.

By focusing on affordability and quality, Pharmascience aims to enhance access to essential medicines, supporting the sustainability of Canada's healthcare system.

Pharmascience's sourcing pattern, characterized by a high degree of concentration with CIPLA LIMITED, presents both challenges and opportunities for new Indian suppliers. While the existing partnership may limit immediate opportunities, Pharmascience's emphasis on affordability and quality suggests potential interest in exploring alternative suppliers that can meet these criteria.